1. Phylogeny  
   Tyrosine‐protein kinase Blk (BLK) is a member of the Src family of non‐receptor tyrosine kinases and is classified into the subfamily typically referred to as the “B‐cell–expressed Src kinases” along with other members such as HCK, LYN, and LCK. BLK is highly conserved among vertebrates and is predominantly expressed in cells of the B-lymphocyte lineage, with orthologs present in all mammalian species. Its evolutionary relationships within the human kinome trace back to early eukaryotic ancestors; like all Src family kinases, BLK shares a common modular architecture that has been maintained through evolution from yeast to man (boggon2004structureandregulation pages 1-2, zhang2021srcfamilyprotein pages 10-11).
2. Reaction Catalyzed  
   BLK catalyzes the phosphorylation of tyrosine residues on protein substrates by transferring the terminal phosphate group from ATP to a target tyrosine residue. The generalized chemical reaction it performs is:  
    ATP + [protein]-tyrosine → ADP + [protein]-phosphotyrosine + H⁺ (template).
3. Cofactor Requirements  
   The catalytic activity of BLK depends on the presence of divalent metal ions. Specifically, Mg²⁺ is required to facilitate ATP binding and proper positioning in the active site, which is a common feature shared by many protein tyrosine kinases (template, boggon2004structureandregulation pages 1-2).
4. Substrate Specificity  
   BLK is responsible for phosphorylating tyrosine residues within key immunoreceptor and adaptor proteins involved in B-cell receptor (BCR) signaling. Experimentally, BLK has been shown to phosphorylate CD79A at Tyr-188 and Tyr-199 and CD79B at Tyr-196 and Tyr-207, which are critical for downstream signal propagation. In addition, BLK can phosphorylate immunoglobulin receptors such as FCGR2A, FCGR2B, and FCGR2C in vitro (barreiro2017functionalstudiesof pages 43-47). Furthermore, microarray analyses of tyrosine kinase substrate specificities have revealed that kinases like BLK generally prefer a motif with an aliphatic residue (Ile, Leu, or Val) at the -1 position, a central tyrosine as the phosphorylation site, followed by a residue such as alanine, glycine, or aspartic acid at the +1 position, and hydrophobic residues (phenylalanine, isoleucine, or leucine) at the +2/+3 positions (deng2014globalanalysisof pages 19-22). These sequence preferences support BLK’s function in precisely targeting tyrosine residues that reside in defined immunoreceptor motifs, such as ITAMs, to regulate B cell activation.
5. Structure  
   BLK exhibits the conserved domain organization characteristic of Src family kinases. At its N-terminus, BLK contains an SH4 domain with a critical glycine residue at position 2 that undergoes N-myristoylation; this lipid modification is essential for binding to the inner leaflet of the plasma membrane and proper subcellular localization (barreiro2017functionalstudiesof pages 40-43, boggon2004structureandregulation pages 1-2). Following the SH4 region, BLK has a unique domain that, although less conserved among family members, is implicated in specifying interactions with cell-specific proteins. The central regions consist of an SH3 domain, which binds proline-rich motifs, and an SH2 domain that recognizes phosphotyrosine-containing sequences; these domains mediate both intramolecular interactions critical for maintaining an auto-inhibited conformation and intermolecular interactions with substrates and regulatory proteins (boggon2004structureandregulation pages 2-3, barreiro2017functionalstudiesof pages 40-43). Downstream of these regulatory modules is the catalytic kinase domain (SH1), which contains key features such as the activation loop—where autophosphorylation at a tyrosine residue (Y389 in BLK) is associated with full catalytic activation—and the C-terminal tail that includes an inhibitory phosphorylation site (Y501) that maintains the kinase in a closed, inactive conformation under basal conditions (barreiro2017functionalstudiesof pages 120-124, boggon2004structureandregulation pages 1-2). Notably, homology modeling approaches have been used to construct three‐dimensional structural models of BLK based on templates from other Src-family kinases, further corroborating its typical domain architecture and providing insights into the spatial arrangement of the activation loop, the hydrophobic spine, and the positioning of the C-helix. Structural studies have also identified that single amino acid variants such as the A71T substitution in the SH3 domain can alter the local structure by introducing additional hydrogen bonds and steric clashes with adjacent residues (e.g., Y69, N73, D76), impacting both the conformation and regulation of the enzyme (barreiro2017functionalstudiesof pages 76-80, barreiro2017functionalstudiesof pages 92-98).
6. Regulation  
   The activity of BLK is intricately regulated by reversible phosphorylation and by protein-protein interactions mediated by its SH2 and SH3 domains. In its inactive state, BLK is predominantly phosphorylated at the C-terminal inhibitory tyrosine (Y501), which promotes an intramolecular interaction with the SH2 domain that locks the kinase in a closed conformation. Activation occurs when dephosphorylation of this inhibitory residue is accompanied by autophosphorylation of a tyrosine residue in the activation loop (Y389), which facilitates the transition to an open and active conformation capable of substrate binding (barreiro2017functionalstudiesof pages 120-124, boggon2004structureandregulation pages 1-2). A notable regulatory mechanism involves the A71T missense variant in the SH3 domain. This substitution disrupts intramolecular interactions that normally stabilize the auto-inhibited conformation, resulting in increased phosphorylation at both tyrosine and threonine residues and enhanced polyubiquitination; this in turn accelerates proteasomal degradation, indicating a balance between enhanced kinase activation and reduced protein stability (barreiro2017functionalstudiesof pages 76-80, barreiro2017functionalstudiesof pages 92-98). In addition, BLK’s membrane localization, mediated by its lipid modifications, is crucial for the regulation of its activity, as proper subcellular targeting facilitates interactions with downstream signaling partners such as phospholipase C gamma 2 (PLCG2) and the B-cell adaptor protein BANK1 (bernalquiros2013bank1andblk pages 4-4, sumera2023pharmacophorebasedhigh pages 1-2).
7. Function  
   BLK plays an essential role in B-lymphocyte signaling, development, and differentiation. It is predominantly expressed in early B cells and persists into mature B cell populations, where it is involved in mediating signals downstream of the B cell receptor (BCR). Upon antigen binding to the BCR, BLK phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) located on the Igα (CD79A) and Igβ (CD79B) subunits, thereby initiating a cascade that includes the recruitment and activation of kinases such as SYK and BTK. This cascade is crucial for propagating signals that lead to B cell activation, proliferation, and differentiation, as well as for controlling transition events such as the pro-B to pre-B cell stage (barreiro2017functionalstudiesof pages 43-47, tretter2003mimicryofpre–b pages 1-2). In addition to its conventional role in BCR signaling, BLK is also involved in modulating alternative signaling pathways. For example, with FYN and LYN, BLK contributes to NF-κB activation—a process particularly relevant in pre-BCR–mediated signaling (barreiro2017functionalstudiesof pages 120-124). Beyond lymphocyte signal transduction, BLK has been implicated in the regulation of pancreatic β-cell function; in pancreatic islets, BLK modulates the expression of transcription factors such as PDX1 and NKX6-1, thereby enhancing insulin secretion in response to glucose stimulation (information). BLK furthermore phosphorylates the cytosolic DNA sensor CGAS, promoting its retention in the cytosol which may have implications for immune regulation (information).
8. Other Comments  
   Targeting BLK pharmacologically has garnered interest because its dysregulation has been associated with autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Genetic polymorphisms in the BLK gene have been linked to altered expression levels in B cells and are associated with increased autoimmune risk (zhang2021srcfamilyprotein pages 6-7). Although direct inhibitors specific for BLK are not extensively documented, screening studies using pharmacophore-based high-throughput virtual screening approaches have identified compounds (e.g., Dasatinib, Ponatinib, and Saracatinib) that bind to highly conserved regions of the kinase domain of Src kinases, and which may also inhibit BLK with favorable binding energies (sumera2023pharmacophorebasedhigh pages 1-2, sumera2023pharmacophorebasedhigh pages 4-8). The interplay between BLK activation, its rapid ubiquitination and degradation (especially in the context of the A71T variant), and its precise substrate phosphorylation underscores the tight regulatory mechanisms required to maintain proper B-cell function and immune tolerance. BLK’s involvement in both oncogenic and immune regulatory pathways makes it a target of high pharmaceutical interest, particularly in hematologic malignancies and autoimmune conditions (barreiro2017functionalstudiesof pages 120-124, bolen1997leukocyteproteintyrosine pages 26-28).
9. References

* barreiro2017functionalstudiesof pages 120-124
* barreiro2017functionalstudiesof pages 43-47
* barreiro2017functionalstudiesof pages 92-98
* bernalquiros2013bank1andblk pages 4-4
* boggon2004structureandregulation pages 1-2
* deng2014globalanalysisof pages 19-22
* sumera2023pharmacophorebasedhigh pages 1-2
* zhang2021srcfamilyprotein pages 10-11
* barreiro2017functionalstudiesof pages 40-43
* barreiro2017functionalstudiesof pages 76-80
* boggon2004structureandregulation pages 2-3
* bolen1997leukocyteproteintyrosine pages 1-4
* bolen1997leukocyteproteintyrosine pages 6-9
* chan1996roleofsrcfamily pages 11-15
* colicelli2010abltyrosinekinases pages 4-5
* gervais1997regulationoflymphocytespecific pages 21-26
* liu2022posttranslationalmodificationsof pages 2-3
* mahajan1995srcfamilyprotein pages 6-7
* mshaik2021studyofthe pages 59-64
* pleiman1993mappingofsites pages 1-2
* sumera2023pharmacophorebasedhigh pages 2-4
* sumera2023pharmacophorebasedhigh pages 4-8
* sumera2023pharmacophorebasedhigh pages 9-9
* tretter2003mimicryofpre–b pages 1-2
* ubau2013functionalcharacterizationof pages 12-15
* ubau2013functionalcharacterizationof pages 15-18
* ubau2013functionalcharacterizationof pages 38-42
* zhang2021srcfamilyprotein pages 1-2
* zhang2021srcfamilyprotein pages 2-4
* zhang2021srcfamilyprotein pages 4-6
* zhang2021srcfamilyprotein pages 6-7
* zhang2021srcfamilyprotein pages 9-10
* bolen1997leukocyteproteintyrosine pages 19-22
* bolen1997leukocyteproteintyrosine pages 26-28
* ingley2008srcfamilykinases pages 1-2
* ingley2008srcfamilykinases pages 2-3
* kettenbach2012rapiddeterminationof pages 2-3
* korademirnics2000srckinasemediatedsignaling pages 2-3
* mahajan1995srcfamilyprotein pages 1-2
* mshaik2021studyofthe pages 56-59
* shah2018finetuningofsubstrate pages 8-10
* ubau2013functionalcharacterizationof pages 89-91
* vizeacoumar2021proteintyrosinekinases pages 1-2

References

1. (barreiro2017functionalstudiesof pages 120-124): A Díaz Barreiro. Functional studies of the sle-risk genes bank1 and blk in b-cell pathways. Unknown journal, 2017.
2. (barreiro2017functionalstudiesof pages 43-47): A Díaz Barreiro. Functional studies of the sle-risk genes bank1 and blk in b-cell pathways. Unknown journal, 2017.
3. (barreiro2017functionalstudiesof pages 92-98): A Díaz Barreiro. Functional studies of the sle-risk genes bank1 and blk in b-cell pathways. Unknown journal, 2017.
4. (bernalquiros2013bank1andblk pages 4-4): Manuel Bernal-Quirós, Ying-Yu Wu, Marta E. Alarcón-Riquelme, and Casimiro Castillejo-López. Bank1 and blk act through phospholipase c gamma 2 in b-cell signaling. PLoS ONE, 8:e59842, Mar 2013. URL: https://doi.org/10.1371/journal.pone.0059842, doi:10.1371/journal.pone.0059842. This article has 61 citations and is from a peer-reviewed journal.
5. (boggon2004structureandregulation pages 1-2): Titus J Boggon and Michael J Eck. Structure and regulation of src family kinases. Oncogene, 23:7918-7927, Oct 2004. URL: https://doi.org/10.1038/sj.onc.1208081, doi:10.1038/sj.onc.1208081. This article has 959 citations and is from a domain leading peer-reviewed journal.
6. (deng2014globalanalysisof pages 19-22): Yang Deng, Nilda L. Alicea-Velázquez, Ludovic Bannwarth, Soili I. Lehtonen, Titus J. Boggon, Heung-Chin Cheng, Vesa P. Hytönen, and Benjamin E. Turk. Global analysis of human nonreceptor tyrosine kinase specificity using high-density peptide microarrays. Journal of Proteome Research, 13:4339-4346, Aug 2014. URL: https://doi.org/10.1021/pr500503q, doi:10.1021/pr500503q. This article has 52 citations and is from a peer-reviewed journal.
7. (sumera2023pharmacophorebasedhigh pages 1-2): Sana Sumera, Sanjai Srinivasan, Harshitha BV, Sharanagoud Biradar, and Shankarrao Patil. Pharmacophore based high throughput virtual screening towards the discovery of novel blk (b-lymphocyte kinase)- tyrosine kinase inhibitors. Indian Journal of Pharmaceutical Education and Research, 57:s174-s182, Mar 2023. URL: https://doi.org/10.5530/ijper.57.1s.21, doi:10.5530/ijper.57.1s.21. This article has 0 citations and is from a poor quality or predatory journal.
8. (zhang2021srcfamilyprotein pages 10-11): Xianzheng Zhang, Dan Mei, Lingling Zhang, and Wei Wei. Src family protein kinase controls the fate of b cells in autoimmune diseases. Inflammation, 44:423-433, Oct 2021. URL: https://doi.org/10.1007/s10753-020-01355-1, doi:10.1007/s10753-020-01355-1. This article has 24 citations and is from a peer-reviewed journal.
9. (barreiro2017functionalstudiesof pages 40-43): A Díaz Barreiro. Functional studies of the sle-risk genes bank1 and blk in b-cell pathways. Unknown journal, 2017.
10. (barreiro2017functionalstudiesof pages 76-80): A Díaz Barreiro. Functional studies of the sle-risk genes bank1 and blk in b-cell pathways. Unknown journal, 2017.
11. (boggon2004structureandregulation pages 2-3): Titus J Boggon and Michael J Eck. Structure and regulation of src family kinases. Oncogene, 23:7918-7927, Oct 2004. URL: https://doi.org/10.1038/sj.onc.1208081, doi:10.1038/sj.onc.1208081. This article has 959 citations and is from a domain leading peer-reviewed journal.
12. (bolen1997leukocyteproteintyrosine pages 1-4): Joseph B. Bolen and Joan S. Brugge. Leukocyte protein tyrosine kinases:potential targets for drug discovery. Annual Review of Immunology, 15:371-404, Apr 1997. URL: https://doi.org/10.1146/annurev.immunol.15.1.371, doi:10.1146/annurev.immunol.15.1.371. This article has 242 citations and is from a highest quality peer-reviewed journal.
13. (bolen1997leukocyteproteintyrosine pages 6-9): Joseph B. Bolen and Joan S. Brugge. Leukocyte protein tyrosine kinases:potential targets for drug discovery. Annual Review of Immunology, 15:371-404, Apr 1997. URL: https://doi.org/10.1146/annurev.immunol.15.1.371, doi:10.1146/annurev.immunol.15.1.371. This article has 242 citations and is from a highest quality peer-reviewed journal.
14. (chan1996roleofsrcfamily pages 11-15): VWF Chan. Role of src-family tyrosine kinase, lyn, in b cell antigen receptor signalling. Unknown journal, 1996.
15. (colicelli2010abltyrosinekinases pages 4-5): John Colicelli. Abl tyrosine kinases: evolution of function, regulation, and specificity. Science Signaling, 3:re6-re6, Sep 2010. URL: https://doi.org/10.1126/scisignal.3139re6, doi:10.1126/scisignal.3139re6. This article has 447 citations and is from a domain leading peer-reviewed journal.
16. (gervais1997regulationoflymphocytespecific pages 21-26): FG Gervais. Regulation of lymphocyte-specific tyrosine protein kinase p56lck by tyrosine phosphorylation. Unknown journal, 1997.
17. (liu2022posttranslationalmodificationsof pages 2-3): Natalie S Liu, Rui Ling, Xiang-Jun Tang, Yunpeng Yu, Yuepeng Zhou, and Deyu Chen. Post-translational modifications of brd4: therapeutic targets for tumor. Frontiers in Oncology, Mar 2022. URL: https://doi.org/10.3389/fonc.2022.847701, doi:10.3389/fonc.2022.847701. This article has 34 citations and is from a peer-reviewed journal.
18. (mahajan1995srcfamilyprotein pages 6-7): Sandeep Mahajan, Joseph Fargnoli, Anne L. Burkhardt, Stephanie A. Kut, Sandra J. Saouaf, and Joseph B. Bolen. Src family protein tyrosine kinases induce autoactivation of bruton’s tyrosine kinase. Molecular and Cellular Biology, 15:5304-5311, Oct 1995. URL: https://doi.org/10.1128/mcb.15.10.5304, doi:10.1128/mcb.15.10.5304. This article has 187 citations and is from a domain leading peer-reviewed journal.
19. (mshaik2021studyofthe pages 59-64): R Mshaik. Study of the effect of hsp90 inhibitors in the treatment of t-all and b-all, by suppressing the lck and lyn signaling pathways. Unknown journal, 2021.
20. (pleiman1993mappingofsites pages 1-2): Christopher M. Pleiman, Marcus R. Clark, Lisa K. Timson Gauen, Sim Winitz, K. Mark Coggeshall, Gary L. Johnson, Andrey S. Shaw, and John C. Cambier. Mapping of sites on the src family protein tyrosine kinases p55blk, p59fyn, and p56lynwhich interact with the effector molecules phospholipase c-γ2, microtubule-associated protein kinase, gtpase-activating protein, and phosphatidylinositol 3-kinase. Molecular and Cellular Biology, 13:5877-5887, Sep 1993. URL: https://doi.org/10.1128/mcb.13.9.5877-5887.1993, doi:10.1128/mcb.13.9.5877-5887.1993. This article has 189 citations and is from a domain leading peer-reviewed journal.
21. (sumera2023pharmacophorebasedhigh pages 2-4): Sana Sumera, Sanjai Srinivasan, Harshitha BV, Sharanagoud Biradar, and Shankarrao Patil. Pharmacophore based high throughput virtual screening towards the discovery of novel blk (b-lymphocyte kinase)- tyrosine kinase inhibitors. Indian Journal of Pharmaceutical Education and Research, 57:s174-s182, Mar 2023. URL: https://doi.org/10.5530/ijper.57.1s.21, doi:10.5530/ijper.57.1s.21. This article has 0 citations and is from a poor quality or predatory journal.
22. (sumera2023pharmacophorebasedhigh pages 4-8): Sana Sumera, Sanjai Srinivasan, Harshitha BV, Sharanagoud Biradar, and Shankarrao Patil. Pharmacophore based high throughput virtual screening towards the discovery of novel blk (b-lymphocyte kinase)- tyrosine kinase inhibitors. Indian Journal of Pharmaceutical Education and Research, 57:s174-s182, Mar 2023. URL: https://doi.org/10.5530/ijper.57.1s.21, doi:10.5530/ijper.57.1s.21. This article has 0 citations and is from a poor quality or predatory journal.
23. (sumera2023pharmacophorebasedhigh pages 9-9): Sana Sumera, Sanjai Srinivasan, Harshitha BV, Sharanagoud Biradar, and Shankarrao Patil. Pharmacophore based high throughput virtual screening towards the discovery of novel blk (b-lymphocyte kinase)- tyrosine kinase inhibitors. Indian Journal of Pharmaceutical Education and Research, 57:s174-s182, Mar 2023. URL: https://doi.org/10.5530/ijper.57.1s.21, doi:10.5530/ijper.57.1s.21. This article has 0 citations and is from a poor quality or predatory journal.
24. (tretter2003mimicryofpre–b pages 1-2): Theresa Tretter, Ashley E. Ross, Dominic I. Dordai, and Stephen Desiderio. Mimicry of pre–b cell receptor signaling by activation of the tyrosine kinase blk. The Journal of Experimental Medicine, 198:1863-1873, Dec 2003. URL: https://doi.org/10.1084/jem.20030729, doi:10.1084/jem.20030729. This article has 83 citations.
25. (ubau2013functionalcharacterizationof pages 12-15): AX Pernudy Ubau. Functional characterization of non-receptor tyrosine kinase dependent signal transduction in acute lymphoblastic leukemia of childhood. Unknown journal, 2013.
26. (ubau2013functionalcharacterizationof pages 15-18): AX Pernudy Ubau. Functional characterization of non-receptor tyrosine kinase dependent signal transduction in acute lymphoblastic leukemia of childhood. Unknown journal, 2013.
27. (ubau2013functionalcharacterizationof pages 38-42): AX Pernudy Ubau. Functional characterization of non-receptor tyrosine kinase dependent signal transduction in acute lymphoblastic leukemia of childhood. Unknown journal, 2013.
28. (zhang2021srcfamilyprotein pages 1-2): Xianzheng Zhang, Dan Mei, Lingling Zhang, and Wei Wei. Src family protein kinase controls the fate of b cells in autoimmune diseases. Inflammation, 44:423-433, Oct 2021. URL: https://doi.org/10.1007/s10753-020-01355-1, doi:10.1007/s10753-020-01355-1. This article has 24 citations and is from a peer-reviewed journal.
29. (zhang2021srcfamilyprotein pages 2-4): Xianzheng Zhang, Dan Mei, Lingling Zhang, and Wei Wei. Src family protein kinase controls the fate of b cells in autoimmune diseases. Inflammation, 44:423-433, Oct 2021. URL: https://doi.org/10.1007/s10753-020-01355-1, doi:10.1007/s10753-020-01355-1. This article has 24 citations and is from a peer-reviewed journal.
30. (zhang2021srcfamilyprotein pages 4-6): Xianzheng Zhang, Dan Mei, Lingling Zhang, and Wei Wei. Src family protein kinase controls the fate of b cells in autoimmune diseases. Inflammation, 44:423-433, Oct 2021. URL: https://doi.org/10.1007/s10753-020-01355-1, doi:10.1007/s10753-020-01355-1. This article has 24 citations and is from a peer-reviewed journal.
31. (zhang2021srcfamilyprotein pages 6-7): Xianzheng Zhang, Dan Mei, Lingling Zhang, and Wei Wei. Src family protein kinase controls the fate of b cells in autoimmune diseases. Inflammation, 44:423-433, Oct 2021. URL: https://doi.org/10.1007/s10753-020-01355-1, doi:10.1007/s10753-020-01355-1. This article has 24 citations and is from a peer-reviewed journal.
32. (zhang2021srcfamilyprotein pages 9-10): Xianzheng Zhang, Dan Mei, Lingling Zhang, and Wei Wei. Src family protein kinase controls the fate of b cells in autoimmune diseases. Inflammation, 44:423-433, Oct 2021. URL: https://doi.org/10.1007/s10753-020-01355-1, doi:10.1007/s10753-020-01355-1. This article has 24 citations and is from a peer-reviewed journal.
33. (bolen1997leukocyteproteintyrosine pages 19-22): Joseph B. Bolen and Joan S. Brugge. Leukocyte protein tyrosine kinases:potential targets for drug discovery. Annual Review of Immunology, 15:371-404, Apr 1997. URL: https://doi.org/10.1146/annurev.immunol.15.1.371, doi:10.1146/annurev.immunol.15.1.371. This article has 242 citations and is from a highest quality peer-reviewed journal.
34. (bolen1997leukocyteproteintyrosine pages 26-28): Joseph B. Bolen and Joan S. Brugge. Leukocyte protein tyrosine kinases:potential targets for drug discovery. Annual Review of Immunology, 15:371-404, Apr 1997. URL: https://doi.org/10.1146/annurev.immunol.15.1.371, doi:10.1146/annurev.immunol.15.1.371. This article has 242 citations and is from a highest quality peer-reviewed journal.
35. (ingley2008srcfamilykinases pages 1-2): Evan Ingley. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1784:56-65, Jan 2008. URL: https://doi.org/10.1016/j.bbapap.2007.08.012, doi:10.1016/j.bbapap.2007.08.012. This article has 435 citations.
36. (ingley2008srcfamilykinases pages 2-3): Evan Ingley. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1784:56-65, Jan 2008. URL: https://doi.org/10.1016/j.bbapap.2007.08.012, doi:10.1016/j.bbapap.2007.08.012. This article has 435 citations.
37. (kettenbach2012rapiddeterminationof pages 2-3): Arminja N. Kettenbach, Tuobin Wang, Brendan K. Faherty, Dean R. Madden, Stefan Knapp, Chris Bailey-Kellogg, and Scott A. Gerber. Rapid determination of multiple linear kinase substrate motifs by mass spectrometry. Chemistry & biology, 19 5:608-18, May 2012. URL: https://doi.org/10.1016/j.chembiol.2012.04.011, doi:10.1016/j.chembiol.2012.04.011. This article has 100 citations.
38. (korademirnics2000srckinasemediatedsignaling pages 2-3): Željka Korade-Mirnics and Seth J Corey. Src kinase-mediated signaling in leukocytes. Journal of Leukocyte Biology, 68:603-613, Nov 2000. URL: https://doi.org/10.1189/jlb.68.5.603, doi:10.1189/jlb.68.5.603. This article has 160 citations and is from a peer-reviewed journal.
39. (mahajan1995srcfamilyprotein pages 1-2): Sandeep Mahajan, Joseph Fargnoli, Anne L. Burkhardt, Stephanie A. Kut, Sandra J. Saouaf, and Joseph B. Bolen. Src family protein tyrosine kinases induce autoactivation of bruton’s tyrosine kinase. Molecular and Cellular Biology, 15:5304-5311, Oct 1995. URL: https://doi.org/10.1128/mcb.15.10.5304, doi:10.1128/mcb.15.10.5304. This article has 187 citations and is from a domain leading peer-reviewed journal.
40. (mshaik2021studyofthe pages 56-59): R Mshaik. Study of the effect of hsp90 inhibitors in the treatment of t-all and b-all, by suppressing the lck and lyn signaling pathways. Unknown journal, 2021.
41. (shah2018finetuningofsubstrate pages 8-10): Neel H Shah, Mark Löbel, Arthur Weiss, and John Kuriyan. Fine-tuning of substrate preferences of the src-family kinase lck revealed through a high-throughput specificity screen. eLife, Mar 2018. URL: https://doi.org/10.7554/elife.35190, doi:10.7554/elife.35190. This article has 65 citations and is from a domain leading peer-reviewed journal.
42. (ubau2013functionalcharacterizationof pages 89-91): AX Pernudy Ubau. Functional characterization of non-receptor tyrosine kinase dependent signal transduction in acute lymphoblastic leukemia of childhood. Unknown journal, 2013.
43. (vizeacoumar2021proteintyrosinekinases pages 1-2): FS Vizeacoumar and A Freywald. Protein tyrosine kinases: their roles and their targeting in leukemia. cancers 2021, 13, 184. Unknown journal, 2021.